The differences in the assessments of side effects at an oncology outpatient clinic
- 408 Downloads
Background There is a growing interest in the use of targeted and immunotherapies in oncology. However, the assessment of side effects can be different due to interpretation of patients’ health status by healthcare professionals in oncology outpatient clinics. Objective To demonstrate the differences in the assessments of side effects conducted independently by a clinical pharmacist and nurses in patients who receive targeted therapies at an oncology outpatient clinic. Setting The study was conducted at the University Oncology Hospital in an outpatient clinic from October 2015 to March 2016. Method Patients receiving ipilimumab, nivolumab, pembrolizumab, bevacizumab, panitumumab or cetuximab during study period were included. The assessment of side effects was conducted by a pharmacist and nurse independently using the NCI-CTCAE version-2. Main outcome measure To compare the severity assessments of side effects between a clinical pharmacist and nurses in an outpatient clinic. Results During the study, 204 visits for 43 patients with a total of 5508 side effect assessments were recorded where 1137 (20.64%) assessments were graded differently. Out of 1137 assessments, 473 of them were graded higher by a clinical pharmacist whereas 664 were graded higher by nurses. Statistically significant differences were detected in the assessment of vomiting, taste changes, sense changes, alopecia, fatigue, mood changes, anxiety, hearing impairment, and allergic reactions. Conclusion An assessment of side effects by healthcare providers in patients with cancer may be challenging due to an increased workload in clinics and undistinguishable symptoms of side effects and cancer itself. Therefore, a new care model which increases an interprofessional communication may improve pharmaceutical care in oncology outpatient clinics.
KeywordsAssessment Immunotherapy Nurse Pharmacist Side effects Targeted therapy Turkey
The authors wish to thank all clinic nurses, medical oncology consultants (Professor Kilickap and Professor Erman from the Hacettepe University Cancer Institute) and the pharmacist, Kelleci-Cakir (Hacettepe University, Department of Clinical Pharmacy) for their greatly appreciated support in this study.
This work was funded by Hacettepe University Scientific Research Coordination Unit. Project Number: TKG-2016-11039.
Conflicts of interest
The authors declare that they have no conflict of interest.
- 1.Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(29):3307–29.CrossRefPubMedGoogle Scholar
- 5.Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–12.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.R Liang, L Zheng. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials. Drug Des Dev Therapy. 2015;9:4471.Google Scholar
- 20.Common Toxicity Criteria: Version 2.0. In: Institute NC, editor. 1999.Google Scholar
- 23.Periasamy U, Mohd Sidik S, Rampal L, Fadhilah SI, Akhtari-Zavare M, Mahmud R. Effect of chemotherapy counseling by pharmacists on quality of life and psychological outcomes of oncology patients in Malaysia: a randomized control trial. Health Qual Life Outcomes. 2017;15(1):104.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Ibraheem AF, Awolude OA, Habeebu M-M, Sowunmi AC, Olaniyi PA, Olopade OI, et al. Formal assessment of teamwork among cancer health care professionals in 3 large tertiary centers in Nigeria. J Clin Oncol. 2017;35(15_suppl):e18126-e.Google Scholar